<- Go Home
Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was founded in 2019 and is based in Naples, Florida.
Market Cap
$4.5M
Volume
1.0M
Cash and Equivalents
$2.1M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$328.00
52 Week Low
$0.37
Dividend
N/A
Price / Book Value
1.42
Price / Earnings
-0.03
Price / Tangible Book Value
1.42
Enterprise Value
$5.3M
Enterprise Value / EBITDA
N/A
Operating Income
-$16.5M
Return on Equity
9415.53%
Return on Assets
-168.26
Cash and Short Term Investments
$2.1M
Debt
$2.9M
Equity
$2.7M
Revenue
N/A
Unlevered FCF
-$15.4M
Sector
Life Sciences Tools and Services
Category
N/A